MADE POSSIBLE BY:
MADE POSSIBLE BY:
Home Tags Daiichi Sankyo

Tag: Daiichi Sankyo

Daiichi Sankyo

Daiichi Sankyo Accelerates BLA Submission for [Fam-] Trastuzumab Deruxtecan in HER2...

Earlier this week Daiichi Sankyo announced plans to accelerate filing of their Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA)...

What are the next generation ADCs?

In the last decade, there have unprecedented advances in discovery of new cytotoxic warheads of different mechanisms, new linkers with highly stable DARs, warhead...

Glycotope and Daiichi Sankyo Sign Licensing Agreement

Building on a previous 2017 option agreement, Daiichi Sankyo and Glycotope, a clinical-stage immuno-oncology company built on world-leading glyco-biology expertise, confirmed that the companies...

DS-8201 Receives SAKIGAKE Designation for Gastric Cancer from Japan’s Ministry of...

DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, has received SAKIGAKE Designation for the treatment of HER2-positive advanced gastric...

Global Phase II Study of DS-8201 in Patients with HER2-Expressing Advanced...

Following initiation of pivotal phase II studies in HER2-positive breast cancer and gastric cancer, the initiation of a third phase II study in colorectal...

Phase I Study of DS-1062 in Patients with Advanced Non-Small Cell...

The first patient has been dosed in a phase I study assessing the safety and tolerability of DS-1062, an investigational trophoblast cell-surface antigen 2...

Clinical Trial with Investigational Potential First-in-class HER3-targeting Antibody-drug Conjugate

A first patient has been dosed in a phase I study evaluating the safety and tolerability of U3-1402, in patients with metastatic or unresectable...

Ongoing Phase I Trial of DS-8201 Demonstrates Confirmed Increased Overall Response...

Updated analysis from ongoing phase I study of DS-8201 (trastuzumab deruxtecan), an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated...

New Data for DS-8201 in Multiple HER2-Expressing Solid Tumors Warrants Further...

In clinical trials, trastuzumab deruxtecan or DS-8201, an investigational HER2-targeting antibody-drug conjugate or ADC being developed by Daiichi Sankyo, demonstrated preliminary antitumor activity in...

Breakthrough Therapy Designation for DS-8201 Confirms the Potential to Offer Substantial...

The U.S. Food and Drug Administration (FDA) earlier today confirmed that it has granted Breakthrough Therapy designation to DS-8201, an investigational HER2-targeting antibody-drug conjugate...